Platelet hemostatic capacity (PHC) and fibrinolytic inhibitors during pregnancy.
Platelet hemostatic capacity (PHC) was measured in blood from pregnant patients during all three trimesters using the PFA-100 system. Closure times were shorter with both cartridge systems during pregnancy, compared to non-pregnant controls, suggesting increased PHC. Thrombin/antithrombin (TAT) complex and prothrombin fragment 1 + 2 (F 1+2) levels were elevated during pregnancy and increased over time. Also, plasma levels of plasminogen activator inhibitor 1 and 2 (PAI-1, PAI-2) increased during pregnancy. The data suggest increased coagulability during pregnancy. It is suggested that estrogen may play a role in this state of hypercoagulability. Seven days after delivery all of the measured parameters, except TAT levels, were again within normal range.
Suzuki
S
S
College of Medical Technology, Hokkaido University, Sapporo, Japan.
Morishita
S
S
D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D005260:Female; D006487:Hemostasis; D006801:Humans; D010447:Peptide Hydrolases / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D017396:Plasminogen Activator Inhibitor 2 / Q000097:blood*; D011247:Pregnancy / Q000097:blood*; D011516:Prothrombin / Q000378:metabolism
D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases